Studying cytochrome P450 kinetics in drug metabolism

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 5, 2008, Pages 591-603

  Kramer, Melissa A ^a   Tracy, Timothy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Atypical; Biphasic; Cytochrome P450; Hepatocytes; Heterotropic activation kinetics; Km; Microsomes; Sigmoidal; Substrate inhibition; Vmax

Indexed keywords

ACETONITRILE; ACYLTRANSFERASE; ALCOHOL; ALPHA NAPHTHOFLAVONE; AMIODARONE; AMITRIPTYLINE; CARBOXYLESTERASE; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3D6; DIMETHYL SULFOXIDE; DIMETHYLANILINE MONOOXYGENASE; EPOXIDE HYDROLASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; METHANOL; METHYLTRANSFERASE; NAPROXEN; PHENANTHRENE; SULFOTRANSFERASE; TOLBUTAMIDE;

BINDING AFFINITY; CATALYSIS; CELL CULTURE; CELL FUNCTION; CHEMICAL REACTION KINETICS; COMPETITIVE INHIBITION; CRYOPRESERVATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; EADIE HOFSTEE PLOT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; HANES WOOLF PLOT; HILL EQUATION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LINEWEAVER BURK PLOT; LIVER CELL; LIVER MICROSOME METABOLISM; MATHEMATICAL MODEL; MICHAELIS MENTEN KINETICS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGMOIDAL KINETICS; SOLVENT EFFECT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; HEPATOCYTES; HUMANS; LIVER; MICROSOMES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 45949107646     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.5.591     Document Type: Review

References (74)

1. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21
2. Craig CR, Stitzel RE. Modern pharmacology with clinical applications. 6th edition. Lippincott, Williams and Wilkins, New York; 2003
3. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403-49
4. Asseffa A, Smith SJ, Nagata K, et al. Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus. Arch Biochem Biophys 1989;274:481-90
5. Buters JT, Korzekwa KR, Kunze KL, et al. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 1994;22:688-92
6. Chernogolov A, Behlke J, Schunck WH, et al. Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral, and catalytical properties and their potency in the formation of all-trans-retinoic acid. Protein Expr Purif 2003;28:259-69
7. Ong CE, Miners JO, Birkett DJ, et al. Baculovirus-mediated expression of cytochrome P4502C8 and human NADPH-cytochrome P450 reductase: optimization of protein expression. N Engl J Med 1998;28:137-52
8. Chen L, Buters JT, Hardwick JP, et al. Coexpression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system. Drug Metab Dispos 1997;25:399-405
9. McGinnity DF, Griffin SJ, Moody GC, et al. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metab Dispos 1999;27:1017-23
10. Raucy JL, Lasker JM. Isolation of P450 enzymes from human liver. Methods Enzymol 1991;206:577-87
11. Pearce RE, Mcintyre CJ, Madan A, et al. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 1996;331:145-69
12. Yamazaki H, Inoue K, Turvy CG, et al. Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome p450 enzymes. Drug Metab Dispos 1997;25:168-74
13. Gomez-Lechon MJ, Donato MT, Casteli JV, et al. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 2004;5:443-62
14. Nelson AC, Huang W, Moody DE. Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. Drug Metab Dispos 2001;29:319-25
15. Nakamura K, Ariyoshi N, Yokoi T, et al. CYP2D6. 10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 2002;293:969-73
16. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199:193-209
17. Patki KC, von Moltke LL, Harmatz JS, et al. Effect of age on in vitro triazolam biotransformation in male human liver microsomes. J Pharmacol Exp Ther 2004;308:874-9
18. Brandon EF, Raap CD, Meijerman I, et al. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 2003;189:233-46
19. Olinga P, Merema M, Hof IH, et al. Effect of human liver source on the functionality of isolated hepatocytes and liver slices. Drug Metab Dispos 1998;26:5-11
20. Olinga P, Merema MT, Hof IH, et al. Effect of cold and warm ischaemia on drug metabolism in isolated hepatocytes and slices from human and monkey liver. N Engl J Med 1998;28:349-60
21. Gomez-Lechon MJ, Lahoz A, Jimenez N, et al. Cryopreservation of rat, dog and human hepatocytes: influence of preculture and cryoprotectants on recovery, cytochrome P450 activities and induction upon thawing. N Engl J Med 2006;36:457-72
22. Hewitt NJ, Buhring KU, Dasenbrock J, et al. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 200;29:1042-50
23. Hewitt NJ, Fischer T, Zuehlke U, et al. Metabolic activity of fresh and cryopreserved cynomolgus monkey (Macaca fascicularis) hepatocytes. N Engl J Med 2000;30:665-81
24. McGinnity DF, Soars MG, Urbanowicz RA, et al. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 2004;32:1247-53
25. Garcia M, Rager J, Wang Q, et al. Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies. In Vitro Cell Dev Biol Anim 2003;39:283-7
26. Roymans D, Annaert P. Van HJ, et al. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 2005;33:1004-16
27. Rodriguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. N Engl J Med 2002;32:505-20
28. Wilkening S, Bader A. Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J Biochem Mol Toxicol 2003;17:207-13
29. Binds D, Lasserre-Bigot D, Bonet A, et al. Time course of cytochromes P450 decline during rat hepacocyte isolation and culture: effect of L-NAME. Toxicol In Vitro 2003;17:59-67
30. Guillouzo A, Morel F, Fardel O, et al. Use of human hepatocyte cultures for drug metabolism studies. Toxicology 1993;82:209-19
31. Auth MK, Woitaschek D, Beste M, et al. Preservation of the synthetic and metabolic capacity of isolated human hepatocytes by coculture with human biliary epithelial cells. Liver Transpl 2005;11:410-9
32. Nahmias Y, Kramvis Y, Barbe L, et al. A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes. FASEB J 2006;20:2531-3
33. Wang YJ, Liu HL, Guo HT, et al. Primary hepatocyte culture in collagen gel mixture and collagen sandwich. World J Gastroenterol 2004;10:699-702
34. Miyamoto Y, Suzuki S, Nomura K, et al. Improvement of hepatocyte viability after cryopreservation by supplementation of long-chain oligosaccharide in the freezing medium in rats and humans. Cell Transplant 2006;15:911-9
35. Lerche-Langrand C, Toutain HJ. Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 2000;153:221-53
36. Guillouzo A, Morel F, Ratanasavanh D, et al. Long term culture of functional hepatocytes. Toxicol In Vitro 1990;4:415-27
37. Fisher RL, Gandolfi AJ, Brendel K. Human liver quality is a dominant factor in the outcome of in vitro studies. Cell Biol Toxicol 2001;17:179-89
38. Vickers AE, Fisher RL. Organ slices for the evaluation of human drug toxicity. Chem Biol Interact 2004;150:87-96
39. Vandenbranden M, Wrighton SA, Ekins S, et al. Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. Drug Metab Dispos 1998;26:1063-8
40. de Kanter R, de Jager MH, Draaisma AL, et al. Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices. Xenobiotica 2002;32:349-62
41. MacGregor JT, Collins JM, Sugiyama Y, et al. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol Sci 2001;59:17-36
42. Hashemi E, Till C, Ioannides C. Stability of cytochrome P450 proteins in cultured precision-cut rat liver slices. Toxicology 2000;149:51-61
43. Renwick AB, Watts PS, Edwards RJ, et al. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2000;28:1202-9
44. Hutzler JM, Wienkers LC, Wahlstrom JL, et al. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 2003;410:16-24
45. Dabrowski MJ, Schrag ML, Wienkers LC, et al. Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J Am Chem Soc 2002;124:11866-7
46. Rock DA, Perkins BN, Wahlstrom J, et al. A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy omega product formation. Arch Biochem Biophys 2003;416:9-16
47. Hummel MA, Gannett PM, Aguilar JS, et al. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry 2004;43:7207-14
48. Hutzler JM, Tracy TS. Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 2002;30:355-62
49. Shou M, Mei Q, Ettore MW Jr, et al. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem 1999;340:845-53
50. Korzekwa KR, Krishnamachary N, Shou M, et al. Evaluation of atypical cytochrome P450 kinetics with two- substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998;37:4137-47
51. Lin Y, Lu P, Tang C, et al. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug metab Dispos 2001;29:368-74
52. Shou M, Grogan J, Mancewicz JA, et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994;33:6450-5
53. Egnell AC, Houston JB, Boyer CS, In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 2003;305:1251-62
54. Hummel MA, Dickmann LJ, Rettie AE, et al. Different activation if CYP2C9 variants by dapsone. Biochem Pharmacol 2004;67:1831-41
55. Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002;91:1923-35
56. Hermann M, Kase ET, Molden E, et al. Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. Curr Drug Metab 2006;7:265-71
57. Yamazaki H, Ueng YF, Shimada T, et al. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH: cytochrome P450 reductase with other flavoproteins, ferredoxin. and oxygen surrogates. Biochemistry 1995;34:8380-9
58. Shet MS, Fisher CW, Holmans PL, et al. Human cytochrome-P450-3A4-enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc Natl Acad Sci USA 1993;90:11748-52
59. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharm. Res. and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32
60. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential: towards a consensus. Br J Clin Pharmacol 2001;52:107-17
61. Busby WF Jr, Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999;27:246-9
62. Tang C, Shou M, Rodrigues AD. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 2000;28:567-72
63. Vuppugalla R, Chang SY, Zhang H, et al. Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes. Drug Metab Dispos 2007;35:1990-5
64. Easterbrook J, Lu C, Sakai Y, et al. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001;29:141-4
65. Chauret N, Gauthier A, Nicollgriffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998;26:1-4
66. Hickman D, Wang JP, Wang Y, et al. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998;26:207-15
67. Cotreau-Bibbo MM, von Moltke LL, Greenblatt DJ. Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes. J Pharm Sci 1996;85:1180-5
68. Palamanda J, Feng WW, Lin CC, et al. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system. Drug Metab Dispos 2000;28:38-43
69. Austin RB Barton P, Cockroft SL, et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30:1497-503
70. McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 2000;49:453-61
71. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350-9
72. Venkatakrishnan K, von Moltke LL, Obach RS, et al. Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 2000;293:343-50
73. Carlile DJ, Zomorodi K, Houston JB. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos 1997;25:903-11
74. Tang C, Lin Y, Rodrigues AD, et al. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 2002;30:648-54